HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Bonafides, Detailing Gynecologists Included In Pharmavite's Third Women’s Health Line

Executive Summary

“This acquisition, plus our existing women's health brands of Equelle and Uqora, positions us, the combined group, as the leader in women's health in nutraceuticals in the US,” says Pharmavite CEO Jeff Boutelle. Bonafide markets supplements for long-term, sustainable support for needs that compound with age, including hot flashes, vaginal dryness, vaginal microbiome and sexual satisfaction.

You may also be interested in...



Sustainable And Ethical VMS Will Drive Consumer Health M&A In 2024

Dietary supplement brands with sustainable and ethical credentials are expected to be popular M&A targets for consumer health firms in 2024, but macroeconomic conditions will likely keep overall deal activity relatively low. 

P&G Clearblue Line Extension, Kenvue Survey Of 4,500 Women Target Menopause Market

P&G announces Clearblue Menopause Stage Indicator launch noting more than two in three women feel unprepared for menopause and less than half say they have enough information to manage it. Kenvue survey results show prior to age 50, proportion of women experiencing symptoms attributable to menopause is significantly greater than the proportion that self-reports.

Bonafide Women’s Health Acquires SAM-e Formulation With High Bioavailability

Women’s health company acquired patent for SAM-e formulation MSI-195 after innovator's study showed it had nearly three times higher availability than a leading competitor.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154240

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel